Showing results (171-180 of 499) with videos related to

Sort By:
Pageof 50
Neuroscience Letters|May 17, 2003
Different binding pattern of antibodies to prion protein on lymphocytes from patients with sporadic Creutzfeldt-Jakob diseasePeter Ratzka, Susanne Döhlinger, Lukas Cepek, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 15, 2009
Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's diseaseVolker Welge, Oliver Fiege, Piotr Lewczuk, et al.
ESC Heart Failure|May 25, 2022
Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failureJan Traub, Markus Otto, Roxane Sell, et al.
Journal of Neurology|December 21, 2024
CSF synaptic biomarkers and cognitive impairment in multiple sclerosisLorenzo Barba, Lorenzo Gaetani, Silvia Sperandei, et al.
Clinical Chemistry and Laboratory Medicine|February 14, 2024
Quantification of blood glial fibrillary acidic protein using a second-generation microfluidic assay. Validation and comparative analysis with two established assaysBadrieh Fazeli, Nerea Gómez de San José, Sarah Jesse, et al.
Journal of Clinical Medicine|December 23, 2022
Hypothermic Oxygenated Machine Perfusion (HOPE) Prior to Liver Transplantation Mitigates Post-Reperfusion Syndrome and Perioperative Electrolyte ShiftsFabian Horné, Moritz Drefs, Malte Joachim Schirren, et al.
Der Nervenarzt|October 7, 2020
[Memory clinics in Germany-structural requirements and areas of responsibility]Lucrezia Hausner, Lutz Frölich, Christine A F von Arnim, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 26, 2025
Serum level changes of the synaptic marker beta-synuclein in Alzheimer's disease continuum and other dementiasLorenzo Barba, Giovanni Bellomo, Daniel Alcolea, et al.
Annals of Clinical and Translational Neurology|August 9, 2023
High diagnostic performance of plasma and cerebrospinal fluid beta-synuclein for sporadic Creutzfeldt-Jakob diseaseSamir Abu-Rumeileh, Steffen Halbgebauer, Giuseppe Mario Bentivenga, et al.
Frontiers in Neurology|April 12, 2019
Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?Ahmed Abdelhak, Tilman Hottenrott, Estrella Morenas-Rodríguez, et al.
Pageof 50